首页> 外文期刊>Cytometry, Part A: the journal of the International Society for Analytical Cytology >Advances in toponomics drug discovery: Imaging cycler microscopy correctly predicts a therapy method of amyotrophic lateral sclerosis
【24h】

Advances in toponomics drug discovery: Imaging cycler microscopy correctly predicts a therapy method of amyotrophic lateral sclerosis

机译:拓扑学药物发现的进展:成像循环显微镜可以正确预测肌萎缩性侧索硬化的治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

An imaging cycler microscope (ICM) is a fully automated (epi)fluorescence microscope which overcomes the spectral resolution limit resulting in parameter- and dimension-unlimited fluorescence imaging. This enables the spatial resolution of large molecular systems with their emergent topological properties (toponome) in morphologically intact cells and tissues displaying thousands of multi protein assemblies at a time. The resulting combinatorial geometry of these systems has been shown to be key for in-vivo/in-situ detection of lead proteins controlling protein network topology and (dys)function: If lead proteins are blocked or downregulated the corresponding disease protein network disassembles. Here, correct therapeutic predictions are exemplified for ALS. ICM drug target studies have discovered an 18-dimensional cell surface molecular system in ALS-PBMC with a lead drug target protein, whose therapeutic downregulation is now reported to show statistically significant effect with stop of disease progression in one third of the ALS patients. Together, this clinical and the earlier experimental validations of the ICM approach indicate that ICM readily discovers in vivo robustness nodes of disease with lead proteins controlling them. Breaking in vivo robustness nodes using drugs against their lead proteins is likely to overcome current high drug attrition rates. (c) 2015 The Author. Published by Wiley Periodicals, Inc, on behalf of ISAC.
机译:成像循环显微镜(ICM)是一种全自动(epi)荧光显微镜,它克服了光谱分辨率的局限性,从而实现了参数和尺寸不受限制的荧光成像。这样可以在形态完整的细胞和组织中同时显示成千上万种多蛋白装配体的情况下,通过其新兴的拓扑特性(拓扑组)对大分子系统进行空间解析。这些系统产生的组合几何结构已被证明是控制蛋白质网络拓扑结构和功能异常的先导蛋白体内/原位检测的关键:如果先导蛋白被阻滞或下调,则相应的疾病蛋白网络将分解。在此,举例说明了ALS的正确治疗预测。 ICM药物靶标研究发现,在ALS-PBMC中具有铅靶蛋白的18维细胞表面分子系统,据报道,其治疗性下调在三分之一的ALS患者中具有统计学显着的作用,可阻止疾病进展。综上所述,ICM方法的临床和较早的实验验证表明,ICM可以通过控制它们的先导蛋白轻松发现疾病的体内稳健性节点。使用针对其先导蛋白的药物打破体内稳健性节点可能会克服当前的高药物消耗率。 (c)2015作者。由Wiley Periodicals,Inc代表ISAC发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号